“…Based on the research progress so far, we can identify various areas that require further exploration, namely: (i) fully leveraging the capabilities of SERS for chemical and biomolecule identification in 3D, (ii) improving multiplexing possibilities, (iii) refining signal processing tools, (iv) addressing limitations towards clinical and practical implementation of SERS, and (v) expanding 3D SERS bioimaging and biosensing beyond 3D cancer models. While SERS has been successfully implemented for the quantitative detection in 2D of a multitude of analytes, including therapeutics, 245 neurotransmitters, 246 metabolites/proteins, [247][248][249] reactive oxygen species, 250,251 DNA, 252 pathogens, 253 and more, 200 still very few works take full advantage of the rich chemical information that SERS can provide in 3D systems. The implementation of label-free SERS in 3D models that recapitulate real biological environments or with ex/in vivo models, could provide key insights at the molecular level for early diagnosis and disease monitoring and/or for the development of novel therapies.…”